Current and future trends in the use of immunosuppressive agents in patients with uveitis

Matthias D. Becker, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish (US)
Pages (from-to)472-477
Number of pages6
JournalCurrent Opinion in Ophthalmology
Volume11
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Uveitis
Immunosuppressive Agents
Cytokines
Cytokine Receptors
Intravenous Immunoglobulins
Photochemotherapy
Antigen Presentation
Cell Adhesion Molecules
T-Lymphocyte Subsets
Neuroprotective Agents
Interleukin-10
Interferons
Adrenal Cortex Hormones
Therapeutics
Apoptosis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Current and future trends in the use of immunosuppressive agents in patients with uveitis. / Becker, Matthias D.; Rosenbaum, James (Jim).

In: Current Opinion in Ophthalmology, Vol. 11, No. 6, 2000, p. 472-477.

Research output: Contribution to journalArticle

@article{1f56ed7bd70b43ca81d1d8a8ec0320ee,
title = "Current and future trends in the use of immunosuppressive agents in patients with uveitis",
abstract = "Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.",
author = "Becker, {Matthias D.} and Rosenbaum, {James (Jim)}",
year = "2000",
doi = "10.1097/00055735-200012000-00015",
language = "English (US)",
volume = "11",
pages = "472--477",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Current and future trends in the use of immunosuppressive agents in patients with uveitis

AU - Becker, Matthias D.

AU - Rosenbaum, James (Jim)

PY - 2000

Y1 - 2000

N2 - Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033668811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033668811&partnerID=8YFLogxK

U2 - 10.1097/00055735-200012000-00015

DO - 10.1097/00055735-200012000-00015

M3 - Article

C2 - 11141644

AN - SCOPUS:0033668811

VL - 11

SP - 472

EP - 477

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 6

ER -